Search research articles
Contact Us
Filters
Showing results (81-90 of 315) with videos related to
Page
of 32
Sort By:
Oncotarget
|
November 24, 2012
Inhibiting the molecular evolution of cancer through HSP90
Ana Sofia Martins, Faith E Davies, Paul Workman
Cancer Cell
|
April 21, 2012
Personalized medicine: patient-predictive panel power
Paul Workman, Paul A Clarke, Bissan Al-Lazikani
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2004
Gene expression microarray technologies in the development of new therapeutic agents
Paul A Clarke, Robert te Poele, Paul Workman
Current Opinion in Pharmacology
|
July 2, 2013
Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology
Paul Workman, Bissan Al-Lazikani, Paul A Clarke
Cell Cycle (Georgetown, Tex.)
|
March 17, 2012
The expanding proteome of the molecular chaperone HSP90
Rahul S Samant, Paul A Clarke, Paul Workman
Cell Cycle (Georgetown, Tex.)
|
August 23, 2011
Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents
Mounia Beloueche-Babari, Paul Workman, Martin O Leach
Proceedings of the National Academy of Sciences of the United States of America
|
April 25, 2014
E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells
Rahul S Samant, Paul A Clarke, Paul Workman
Drug Discovery Today
|
February 2, 2020
From patent to patient: analysing access to innovative cancer drugs
Eva Sharpe, Richard Hoey, Christina Yap, et al.
Plos One
|
May 26, 2017
SiGNet: A signaling network data simulator to enable signaling network inference
Elizabeth A Coker, Costas Mitsopoulos, Paul Workman, et al.
Methods (San Diego, Calif.)
|
June 11, 2002
Assays for the identification and evaluation of histone acetyltransferase inhibitors
G Wynne Aherne, Martin G Rowlands, Lindsay Stimson, et al.
Page
of 32
Search research articles
Search
Showing results (81-90 of 315) with videos related to
Sort By:
Page
of 32
Oncotarget
|
November 24, 2012
Inhibiting the molecular evolution of cancer through HSP90
Ana Sofia Martins, Faith E Davies, Paul Workman
Cancer Cell
|
April 21, 2012
Personalized medicine: patient-predictive panel power
Paul Workman, Paul A Clarke, Bissan Al-Lazikani
European Journal of Cancer (Oxford, England : 1990)
|
November 16, 2004
Gene expression microarray technologies in the development of new therapeutic agents
Paul A Clarke, Robert te Poele, Paul Workman
Current Opinion in Pharmacology
|
July 2, 2013
Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology
Paul Workman, Bissan Al-Lazikani, Paul A Clarke
Cell Cycle (Georgetown, Tex.)
|
March 17, 2012
The expanding proteome of the molecular chaperone HSP90
Rahul S Samant, Paul A Clarke, Paul Workman
Cell Cycle (Georgetown, Tex.)
|
August 23, 2011
Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents
Mounia Beloueche-Babari, Paul Workman, Martin O Leach
Proceedings of the National Academy of Sciences of the United States of America
|
April 25, 2014
E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells
Rahul S Samant, Paul A Clarke, Paul Workman
Drug Discovery Today
|
February 2, 2020
From patent to patient: analysing access to innovative cancer drugs
Eva Sharpe, Richard Hoey, Christina Yap, et al.
Plos One
|
May 26, 2017
SiGNet: A signaling network data simulator to enable signaling network inference
Elizabeth A Coker, Costas Mitsopoulos, Paul Workman, et al.
Methods (San Diego, Calif.)
|
June 11, 2002
Assays for the identification and evaluation of histone acetyltransferase inhibitors
G Wynne Aherne, Martin G Rowlands, Lindsay Stimson, et al.
Page
of 32